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The Met Allele of the BDNF Val66Met Polymorphism
Predicts Poor Outcome Among Survivors of Aneurysmal
Subarachnoid Hemorrhage
Jari Siironen, MD, PhD; Seppo Juvela, MD, PhD; Katarzyna Kanarek, MS; Juhani Vilkki, PhD;
Juha Hernesniemi, MD, PhD; Jaakko Lappalainen, MD, PhD
Background and Purpose—Brain-derived neurotrophic factor (BDNF) plays a role in neuronal survival, plasticity and
neurogenesis. The BDNF gene contains a common Val66Met polymorphism; the Met allele is associated with lower
depolarization-induced BDNF release and differences in memory functions and brain morphology. We hypothesized that
the Met allele is associated with poor recovery from subarachnoid hemorrhage.
Methods—A sample of 105 survivors was assessed at 3 months after subarachnoid hemorrhage using Glascow Outcome
Scale. Poor outcome was defined as severe disability or worse. DNA samples were genotyped for the Val66Met
polymorphism.
Results—Higher percentage of the Met carriers had a poor outcome (29%) as compared with the Val/Val group (10%;
P0.011). In multiple logistic regression, this association between the Met allele and poor outcome was independent
of several other prognostic factors such as patient age, clinical condition, and radiological severity of the bleeding (odds
ratio 8.40; 95% CI, 1.60 to 44.00; P0.012).
Conclusions—Genetically influenced variation in BDNF function plays a role in recovery from subarachnoid hemorrhage.
These data indicate that augmentation of BDNF signaling may be beneficial to recovery from brain injury. (Stroke.
2007;38:2858-2860.)
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Aneurysmal subarachnoid hemorrhage (SAH) is a severemedical illness, which among survivors is associated
with disability, cognitive deficits, psychosocial impairments
and lower quality of life.1 Age, neurological condition on
admission, and factors related to the severity and complica-
tions of SAH are predictive of mortality and recovery.1,2
However, a significant amount of variation in the long-term
recovery from SAH remains unexplained.
Brain-derived neurotrophic factor (BDNF) plays a major
role in neuronal survival, neurogenesis and synaptic plastic-
ity.3 For example, BDNF attenuates glutamate toxicity and
rescues cerebellar neurons from cell death. Animal studies
show that BDNF reduces ischemic injury and improves
functional recovery and postinjury regeneration.4,5
BDNF contains a Val66Met polymorphism in the 5
proregion of the protein. In vitro studies using transfected
neurons suggest that the Met allele decreases BDNF traffick-
ing into secretory granules. Furthermore, lower depolarization-
induced BDNF secretion in the Met-BDNF transfected neurons
was reported while constitutive secretion in these neurons
remained unchanged.6 In humans, increasing body of evi-
dence supports that the Val66Met is associated with a
complex neuronal phenotype involving memory and subtle
differences in brain morphology.6,7,8,9 For example, subjects
with the Met allele have lower performance in tests measur-
ing episodic memory, and lower hippocampal and prefrontal
cortical gray matter volumes.6,8
Considering the role of BDNF in neuronal survival and
neuroplasticity, we hypothesized that the Met allele is asso-
ciated with poor outcome of recovery as compared with the
Val allele among SAH survivors.
Materials and Methods
Subjects
Subjects of this study were 105 SAH survivors who had participated
in a clinical trial testing the efficacy of enoxaparin on the outcome of
SAH10 (Table 1). The results of the study, which were negative, were
reported earlier.10 All patients were assessed using the Glascow
Outcome Scale1,2,10 at the outpatient department 3 months after the
SAH. Poor outcome was defined by Glascow Outcome Scale as
severe disability or worse. All patients were rated by J.S. who was
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blind to the genotypes of the subjects. Neurological condition on
admission was determined using the World Federation of Neurolog-
ical Surgeons (WFNS) scale.1,2,10 All subjects were Finnish.
Genetic Analysis
Genomic DNA was extracted using the Gentra PureGene kits from
buccal cells. BDNF Val66Met was genotyped using PCR-RFLP.11
About 25% of the samples were analyzed as duplicate for quality
control purposes with perfect concordance of the results. Met/Met
homozygotes (n3) were grouped together with Met/Val heterozy-
gotes (n31). The Met allele frequency in this population was 18%.
Statistical Analysis
For univariate statistics, conventional statistical tests were used.
Univariate and multivariate odds ratios and 95% CI of risk factors,
including their interactions, for poor outcome at 3 months were
analyzed with unconditional logistic regression. The variables tested
included established factors for poor outcome: age, clinical condition
(WFNS grade), presence of intraventricular bleeding, intracerebral
hemorrhage10 mm in diameter, Fisher grade 3 (defined as1 mm
of blood in vertical layers in CT), plasma glucose and D-dimer
concentrations on admission.1,2
Results
Of the subjects with the Met allele (n34), 29% had a poor
outcome (n10) and 71% had a favorable outcome (n24).
Of the Val/Val subjects, 10% had a poor outcome (n7) and
90% had a favorable outcome (n64; P0.011). Multiple
logistic regression analysis showed that the Met allele is
associated with poor outcome independent of other prognos-
tic factors (Table 2).
Discussion
The major finding in this study is that the Met allele of the
BDNF Val66Met polymorphism is associated with poor
outcome of recovery at 3 months after SAH. In our sample,
29% of the Met carriers had a poor outcome whereas in the
Val/Val genotype group 10% of the subject had this outcome
(P0.011). The effect of the Met allele was independent of
other known predictors of poor outcome (Table 2). These
findings are in agreement with the data supporting the role of
BDNF in neuronal survival and neuroplasticity.4,5 Further-
more, these data suggest that targeting BDNF signaling may
promote recovery from SAH.
Although these data do implicate BDNF in recovery from
SAH, they do not tell us about the mechanisms leading to
better functioning. Glascow Outcome Scale is a simple
clinician-rated instrument used to assess subject’s level of
disability irrespective of whether the disability is due, for
example, to cognitive or motor deficits.1,2,10 Future studies
should address whether the effects of the Val66Met are
mediated through cognitive mechanisms, such as memory, as
suggested by previous studies.6,7,9
One caveat of this study is that the sample is not represen-
tative of all SAH survivors. Because enrollment to this study
was through a previous clinical trial, survivors with the most
complicated cases of SAH were excluded.10 Thus, the popu-
lation in this study is biased toward better outcome. On the
other hand, reduction in clinical variation by exclusion of
subjects with severe SAH, among whom genetic effects on
recovery are unlikely to be seen, may have allowed the BDNF
effect to be discovered. Regardless of this sampling bias, we
feel that the findings are important and open new vistas
toward understanding neurobiological mechanisms contribut-
ing to recovery from brain trauma. This bias should be borne
in mind, however, if attempts are made to replicate these
findings. Another caveat of the study is that the sample size
was relatively small. Replication attempts in independent
populations are thus warranted. Considering that all subjects
Table 1. Characteristics of 105 Patients With SAH
Met (n34) Val/Val (n71)
Female 14 (41%) 38 (54%)
Age (meanSD) 46.1 (10.0) 48.4 (11.8)
Plasma glucose mmol/L
SD on admission
8.42 (2.16) 8.06 (2.20)
D-dimer, g/L
SD after surgery
1095 (1106) 1270 (1093)
Fisher grade 3* 24 (71%) 49 (69%)
IVH
no 19 (56%) 39 (55%)
slight 12 (35%) 27 (38%)
moderate to severe 3 (9%) 5 (7%)
ICH 10 mm in diameter 3 (9%) 4 (6%)
Symptoms of spasm
no 26 (77%) 55 (78%)
reversible 3 (9%) 6 (9%)
fixed 5 (15%) 10 (14%)
WFNS grade on admission
I 23 (68%) 39 (55%)
II–III 6 (18%) 17 (24%)
IV–V 5 (15%) 15 (21%)
*Defined as 1 mm of blood in vertical layers in CT.
IVH indicates intraventricular hemorrhage; ICH, intracerebral hemorrhage;
WFNS, World Federation of Neurosurgical Societies.1,2,10
Table 2. Risk Factors for Poor Outcome After Aneurysmal SAH
Univariate Multivariate
OR 95% CI OR 95% CI
Age (per year) 1.05 (1.00–1.11) 1.08 0.98–1.20
Plasma glucose at
admission, per mmol/L
1.33 (1.05–1.68)* 1.13 0.79–1.61
D-dimer, per mg/L 1.86 (1.19–2.90)† 1.82 0.98–3.40
WFNS
1 1 1
2–5 3.21 (1.08–9.50)* 3.63 0.74–17.97
IVH 5.16 (1.56–17.14)† 4.32 0.82–22.73
Fisher 3** 3.88 (0.83–18.09) 2.62 0.17–41.33
ICH 5.69 (1.50–21.58)* 7.60 1.12–51.48*
Met allele
No 1 1
Yes 3.81 (1.30–11.15)* 8.40 1.60–44.00*
OR indicates odds ratio; WFNS, World Federation of Neurosurgical Societies;1,2,10
IVH, intraventricular hemorrhage.
*P0.05; †P0.01.
**Defined as 1 mm of blood in vertical layers in CT.
ICH 10 mm in diameter.
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were Finns, we feel that likelihood of the findings resulting
from population stratification is low.
In summary, these data support that genetically influenced
variation in BDNF function is associated with recovery from
SAH. These findings suggest that targeting BDNF signaling
may enhance recovery from brain injury.
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